China Filed 3,073 IND Applications in 2024. The West Hasn’t Noticed What That Number Actually Means.

Pull up China’s Center for Drug Evaluation annual report for 2024 and find the IND acceptance figure: 3,073 new drug clinical trial applications. Now scroll back to 2015, when that number was 70. In less than a decade, China’s clinical trial machine has undergone a 44-fold expansion — and most Western sponsors are still treating it as a secondary market, a recruitment supplement, or a regulatory afterthought. That misreading is becoming expensive.

The instinct inside most global pharma strategy teams is to frame China’s trial growth as volume without sophistication — a country catching up on process while the real science happens in Boston and Basel. But by the end of 2024, domestic drugs constituted 86.8% of the 167 innovative drugs approved in China, up from a fraction of that share in 2018. China’s pipeline is no longer being populated by Western imports. It is being built indigenously, at scale, at speed — and increasingly under a regulatory framework that is starting to challenge, not merely imitate, ICH norms.

That shift creates a strategic dilemma for global sponsors that no one in the industry wants to say plainly: the window for setting trial design standards in China on Western terms is closing.

The Regulatory Rebuild Nobody Briefed You On

The architecture behind that 44-fold IND increase did not happen by accident. China’s NMPA spent the years between 2015 and 2020 systematically dismantling the regulatory bottlenecks that had made running a trial in China operationally brutal. Protocol amendment approvals, once a bureaucratic black hole, were rationalized: under NMPA’s 2020 drug registration provisions, changes to protocol, CMC, and nonclinical elements that do not affect patient safety no longer require NMPA approval at all. The CTA amendment timeline for changes that do require review was standardized to 60 working days. For sponsors accustomed to open-ended FDA Type A meeting requests and amendment review queues that can stretch past 90 days, that structure is not merely competitive — it is operationally attractive.

Then came the ICH alignment. In December 2019, NMPA Announcement No. 88 formally adopted ICH E11(R1) on pediatric drug investigation, taking effect six months later — a deliberate, compliance-ready runway that most Western regulatory bodies would recognize as textbook implementation. China’s accession to ICH full membership in 2017 was the symbolic headline; the quiet procedural harmonization that followed is what actually matters to protocol writers and IND teams.

But harmonization with ICH is not the same as convergence with FDA expectations — and that gap is where global sponsors are making operationally costly assumptions.

Consider what happens when a sponsor designs a Phase III oncology trial intended to support simultaneous submissions to FDA, EMA, and NMPA. The endpoint package acceptable to FDA’s Oncology Center of Excellence may not map cleanly onto CDE’s evolving preferences for domestically-relevant comparator arms. China’s patient population carries distinct pharmacogenomic profiles in oncology — CYP2C19 polymorphism frequencies differ markedly from Western cohorts — and a trial powered on Western demographic assumptions can produce efficacy data that CDE reviewers find structurally thin for Chinese patients. That is not a hypothetical. It is the operational reality behind why so many multinational submissions in oncology and CNS are generating supplementary data requests from CDE that were not anticipated at protocol design.

The RWE Accelerant Western Sponsors Are Ignoring

Here is the counterintuitive position on China’s trial landscape that most industry observers will resist: China’s real-world evidence infrastructure is advancing faster than its randomized trial infrastructure, and that may ultimately be more consequential for how global drug development works.

In 2022, CDE issued a draft guideline on real-world study design methods — covering observational designs, registries, and pragmatic trials — as part of a deliberate regulatory push to build RWE into the evidentiary architecture for drug approvals. China’s national health records system, which spans a population of 1.4 billion under a relatively centralized electronic health infrastructure, creates a data substrate for RWE generation that FDA-regulated sponsors can only approximate through fragmented payer claims databases and EHR networks. The scale of accessible longitudinal patient data in China is not comparable to anything available in the United States for routine clinical research purposes.

Most Western sponsors treat this as someone else’s problem — a regulatory detail for China-specific submissions. That framing misses the trajectory.

If CDE continues to build RWE acceptance criteria into its approval standards for label expansions and post-market commitments, and if that framework gains enough credibility to influence ICH discussion on RWE harmonization, the downstream effect on FDA-regulated trial design could be significant. The FDA’s own RWE framework evolution since 2018 has been deliberate but cautious — constrained by the epistemological conservatism built into the agency’s randomized evidence tradition. A Chinese regulatory system willing to move faster on RWE acceptance, backed by population-scale data, creates a proof-of-concept pressure that FDA will eventually have to engage with.

The assumption that RWE standards flow from West to East is exactly the kind of directional certainty that the IND application numbers should already be unsettling.

What Global Sponsors Must Rethink Now

China does not have formal bilateral mutual recognition agreements for clinical trial data — the NIAID regulatory overview confirms that NMPA’s acceptance of overseas data operates through unilateral policy reform, not reciprocal treaty. For sponsors, that distinction matters operationally: there is no guarantee structure, no binding precedent framework, no mechanism analogous to EMA-FDA parallel scientific advice for navigating simultaneous submissions. Every multinational trial that includes Chinese sites is navigating two parallel regulatory relationships — one with FDA or EMA, one with NMPA — without a formal bridge between them.

That structural gap demands a protocol architecture decision that most sponsors are still making too late in development. The question of whether a trial is designed to be China-inclusive from IND, or China-supplemented after the fact, determines whether Chinese patients are enrolled under the same statistical assumptions as Western cohorts or shoehorned into a secondary analysis that CDE will treat as exploratory. CDE has been increasingly explicit in its technical guidance that post-hoc bridging studies — where a Western trial with limited Chinese enrollment is supplemented by a small domestic cohort — are insufficient for establishing efficacy in the Chinese population for novel mechanisms. The IND data tells the story: sponsors are filing in China at scale because they have learned that lesson, often after an expensive missed submission cycle.

The 3,073 IND applications accepted in 2024 represent more than a regulatory throughput statistic. They represent the revealed preference of the global drug development community, filing at a rate that was institutionally impossible in 2015. What sponsors cannot afford is the lag between that filing behavior and the strategic protocol design decisions that should follow from it — because the sponsors building China-native trial designs from day one, with domestically-relevant endpoints and population assumptions, are not waiting for the West to set the standard. They are writing it.

References

1. Nature Reviews Drug Discovery — “Trends in the landscape of clinical trials of innovative drugs in China since 2015”
2. PMC / NCBI — China CDE IND application statistics 2015–2020
3. PMC / Clinical Pharmacology & Therapeutics — “Innovative Drugs Approved in China After Registration Classification Reform: Current Status, Disparities, and Challenges” (domestic drug share 86.8% by end of 2024)
4. NMPA Announcement No. 88 (December 19, 2019) — ICH E11(R1) Adoption
5. PPD Regulatory Insights — “Focus on China: New Provisions for Drug Registration in 2020” (NMPA CTA amendment timelines)
6. Frontiers in Medicine — CDE RWE draft guideline 2022 and China real-world evidence regulatory framework
7. NIAID ClinRegs — China regulatory overview (overseas clinical trial data acceptance policy)